Latest revenue
$30.9M
as of 2026-03-31
Latest net income
$-15.9M
as of 2026-03-31
Net margin
-51.4%
as of 2026-03-31
Community sentiment
Where do you think RXST is heading?
Keep private notes on RXST — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
RXST vs S&P 500 · rebased to 100
Live market
delayed ≤15 min- Market cap
- $195.2M
- Enterprise value
- $177.6M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- 0.73×
- Dividend yield
- 0.0%
- 52-wk high
- $14.88
- 52-wk low
- $4.48
- Beta
- —
- Shares out
- 41.4M
What this company does
Item 1. Business Overview RxSight, Inc. is a commercial-stage medical technology company dedicated to providing high-quality customized vision to patients following cataract surgery. Our proprietary RxSight® Light Adjustable Lens system (“RxSight system”) is the first and only commercially available premium cataract technology that enables doctors to customize and optimize visual acuity for patients after surgery. The RxSight system is comprised of our RxSight Light Adjustable Lens®(LAL®/LAL+®, collectively the “LAL”), RxSight Light Delivery Device (“LDD™”) and related accessories. The LAL is a premium intraocular lens (“IOL”) made from the proprietary silicone-based photosensitive material…
AI summary unavailable — showing raw filing excerpt
Generated from RXST's filing dated 2026-02-25
Key risks
Item 1A. Risk Factors We operate in a rapidly changing environment that involves numerous uncertainties and risks. In addition to the other information included in this report, the following risks and uncertainties may have a material and adverse effect on our business, financial condition, results of operations, or stock price. You should consider these risks and uncertainties carefully, together with all of the other information included or incorporated by reference in this report. The risks and uncertainties described below may not be the only ones we face. If any of the risks or uncertainties we face were to occur, the trading price of our securities could decline, and you may lose all…
AI summary unavailable — showing raw filing excerpt
Generated from RXST's filing dated 2026-02-25
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Ophthalmic Goods (7 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 13, 2026.